China Biologic Products Holdings, Inc. (NASDAQ:CBPO) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus price objective of $111.67 for the company and are anticipating that the company will post $1.11 earnings per share for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 98 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th.

China Biologic Products (NASDAQ:CBPO) opened at $80.25 on Thursday. The company has a market cap of $2,263.41, a PE ratio of 18.26, a price-to-earnings-growth ratio of 1.34 and a beta of 1.78. China Biologic Products has a 1 year low of $72.21 and a 1 year high of $120.46.

Several hedge funds have recently added to or reduced their stakes in the stock. AXA increased its stake in shares of China Biologic Products by 35.9% during the third quarter. AXA now owns 128,220 shares of the biopharmaceutical company’s stock worth $11,831,000 after buying an additional 33,886 shares during the period. California Public Employees Retirement System increased its stake in China Biologic Products by 51.7% in the third quarter. California Public Employees Retirement System now owns 44,757 shares of the biopharmaceutical company’s stock valued at $4,130,000 after purchasing an additional 15,257 shares during the last quarter. Cubist Systematic Strategies LLC increased its stake in China Biologic Products by 73.2% in the third quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock valued at $426,000 after purchasing an additional 1,952 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in China Biologic Products by 31.0% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 363,190 shares of the biopharmaceutical company’s stock valued at $33,511,000 after purchasing an additional 85,909 shares during the last quarter. Finally, Temasek Holdings Private Ltd purchased a new position in China Biologic Products in the third quarter valued at approximately $3,414,000. Hedge funds and other institutional investors own 65.67% of the company’s stock.

WARNING: “Analysts Expect China Biologic Products Holdings, Inc. (CBPO) to Post $1.11 EPS” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/analysts-expect-china-biologic-products-holdings-inc-cbpo-to-post-1-11-eps.html.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.